Perianal condylomas, anal squamous intraepithelial neoplasms and screening: A review of the literature

Journal of Medical Screening

Volumn 17, Issue 1, 2010, Pages 44-49

  Oon, Sheng Fei ^a   Winter, Desmond C ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS TUMOR; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 77950633388     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2009.009058     Document Type: Review

References (58)

1. Jay N, Berry JM, Hogeboom CJ, et al. Colposcopic appearances of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 1997;40:919
2. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987;317:973-7
3. Genital HPV Infection Fact Sheet. Atlanta: Centers for Disease Control and Prevention, 2009. See http://www.cdc.gov/std/HPV/STDFact-HPV.htm (last checked 13 September 2009)
4. Pfister H. The role of human papillomaviruses in anogenital cancer. Obstet Gynecol Clin North Am 1996;23:579
5. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999;59:753-757
6. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-80
7. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl. 3):S3/11-25
8. Darragh TM. Anal cytology for anal cancer screening: is it time yet? Diagn Cytopathol 2004;30:371-374
9. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375-83
10. Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994;8:283
11. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9
12. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-288
13. Chiao EY, Krown SE, STier EA, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005;40:451-5
14. Robinson D, Coupland V, Møller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009;100:527-31
15. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361
16. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-280
17. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989;81:1726-31
18. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-9
19. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 2005;97:896
20. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998;12:495
21. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138:453-9
22. Maggard MA, Beanes SR, Ko CY. Anal canal cancer: a population-based reappraisal. Dis Colon Rectum 2003;46:1517-23; discussion 1523-4; author reply 1524
23. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994;139:772-780
24. Williams AB, Darragh TM, Vranizan K, Ochia C, Moss AR, Palefsky JM. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994;83:205-11
25. Holly EA, Ralton ML, Darragh TM, et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843
26. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009;27:884-90
27. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005;19:1407
28. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:314-319
29. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:320-6 (Pubitemid 128606007)
30. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-32 (Pubitemid 40528605)
31. Grulich AE, Wan X, Law MG, Coates M, Kaldor JM. Risk of cancer in people with AIDS. AIDS 1999;13:839-843 (Pubitemid 29224587)
32. Petruckevitch A, Del Amo J, Phillips AN, Stephenson JM, Johnson AM, De Cock KM. Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Int J STD AIDS 1999;10:38-42
33. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acqur Immune Defic Syndr 2004;37: 1563-5 (Pubitemid 39658192)
34. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001;28:422-8 (Pubitemid 34033192)
35. Goldman S, Auer G, Erhardt K, Seligson U. Prognostic significance of clinical stage, histologic grade, and nuclear DNA content in squamous-cell carcinoma of the anus. Dis Colon Rectum 1987;30:444-8 (Pubitemid 17093136)
36. Lindsey K, DeCristofaro C, James J. Anal Pap smears: should we be doing them? J Am Acad Nurse Pract 2009;21:437-43
37. Matthews WC. Screening for anal dysplasia associated with human papillomavirus. Top HIV Med 2003;11:45-9
38. Goldie SJ, Kuntz KM,Weinstein MC, Freedberg KA,Welton ML, Palefsky JM. The costs, clinical benefits, and cost effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999;130:97-107
39. Goldie SJ, Kuntz KM,Weinstein B, Freedberg KA,Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-9
40. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000;108:634-41
41. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006;43:223-33
42. Matthews C, Mar-Tang M, Smith D, Saville W, Cosman B. Reproducibility and outcomes of anal dysplasia screening in an HIV primary care clinic. Ninth Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA [Abstract 605-W.]
43. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:415-22 (Pubitemid 27225314)
44. Matthews WC, Sitapati A, Caperna JC, Barber RE, Tugend A, Go U. Measurement characteristics of anal cytology, histopathology and high-resolution anoscopic visual impression in an anal dysplasia screening program. J Acquir Immune Defic Syndr 2004;37:1610-5 (Pubitemid 39658202)
45. Mayeaux EJ Jr, Harper MB, Abreo F, Pope JB, Phillips GS. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology. J Fam Pract 1995;40:57-62
46. DiBonito L, Falconieri G, Tomasic G, Colautti I, Bonifacio D, Dudine S. Cervical cytopathology: an evaluation of its accuracy based on cytohistologic comparison. Cancer 1993;72:3002-3006 (Pubitemid 23335047)
47. Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004;5:149-57 (Pubitemid 38262846)
48. Northover JM. Epidermoid cancer of the anus - the surgeon retreats. J R Soc Med 1991;84:389-90
49. Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994;343:32-4 (Pubitemid 24017614)
50. Klencke B, Matijevic M, Urban R, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8:1028-37 (Pubitemid 34517636)
51. Palefsky, Goldstone SE, Winnett M, Siegel MI, Neefe JR. HspE7 treatment of anal dysplasia: results of an open-label trial of HspE7 and comparison with a prior controlled trial of low dose HspE7. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 22-25 September 2001, Chicago, IL [Abstract H-1600.]
52. Gardasil, European Public Assessment Report. EPARS for authorised medicinal products for human use. London: European Medicines Agency, 2009. See http://www.ema.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm (last checked 18 September 2009)
53. Cervarix, European Public Assessment Report. EPARS for authorised medicinal products for human use. London: European Medicines Agency, 2009. See http://www.ema.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm (last checked 18 September 2009)
54. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-51 (Pubitemid 351213674)
55. Kulasingam SL, Bernard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008;6:4 (Pubitemid 351158538)
56. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97:1322-1328 [Epub ahead of print 9 October 2007] (Pubitemid 350035812)
57. Product news: FDA Advisory Committee Recommends Approval for Use of GARDASIL® in Boys and Men. New Jersey: Where patients come first, Merck. 2009. See http://www.merck.com/newsroom/press-releases/product/2009-0909.html (last checked 18 September 2009)
58. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl. 10):K53-61